Avadel Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 10th

DUBLIN, Ireland , July 27, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, August 10, 2020 , to provide a corporate update and discuss the Company's financial results for the second

Avadel Pharmaceuticals Announces First Patient Dosed in Open-Label Extension/Switch Study of Investigational Once-Nightly FT218 as a Potential Treatment for Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy

Clinical study to enroll 250 patients from sites that participated in the REST-ON study Study to examine the long-term safety and maintenance of efficacy in patients, and evaluate dosing and preference for patients switching from twice-nightly sodium oxybate to once-nightly FT218 DUBLIN, Ireland ,

Avadel Announces Sale of Hospital Sterile Injectable Drug Portfolio for $42.0 Million

DUBLIN, Ireland , July 01, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, today announced

Avadel Pharmaceuticals to Present at BIO Digital

DUBLIN, Ireland , June 08, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, today announced

Avadel Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference

DUBLIN, Ireland , June 01, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, today announced

Avadel Pharmaceuticals Reports First Quarter 2020 Financial Results

Reported positive topline data from the pivotal Phase 3 REST-ON study Strengthened balance sheet with $190 million in gross proceeds from a private placement in February 2020 and public equity offering in May 2020 Reported revenue of $12.2 million for the first quarter of 2020 Management to

Avadel Pharmaceuticals to Report First Quarter 2020 Financial Results on May 11th

DUBLIN, Ireland , May 04, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, announced today

Avadel Pharmaceuticals Announces Pricing of Public Offering

DUBLIN, Ireland , April 28, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, announced today

Avadel Pharmaceuticals Announces Proposed Underwritten Public Offering

DUBLIN, Ireland , April 27, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, announced today

Avadel Pharmaceuticals Announces Positive Topline Results from its Pivotal Phase 3 REST-ON Trial of Once-Nightly FT218 for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy

The primary analysis of investigational, once-nightly FT218 at 9 g demonstrated highly statistically significant (p

Avadel Pharmaceuticals Completes the REST-ON Phase 3 Pivotal Trial of FT218 for Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy

Topline data from the REST-ON study expected in Q2 2020 DUBLIN, Ireland , March 25, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for the treatment of excessive daytime

Avadel Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results

Completed enrollment for the pivotal REST-ON Phase 3 study in Q4 2019; data readout expected in Q2 2020 Raised $65 million in gross proceeds from private placement with leading biotech investment funds in February 2020 Realized over $80 million in cost savings from restructuring and other cost

Avadel Pharmaceuticals to Report Fourth Quarter and Year End 2019 Financial Results on March 12th

DUBLIN, Ireland , Feb. 27, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, announced today

Avadel Pharmaceuticals Announces $65 Million Private Placement with Leading Biotech Investment Funds

DUBLIN, Ireland , Feb. 21, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, announced today

Avadel Pharmaceuticals Completes Enrollment in the REST-ON Phase 3 Pivotal Trial of FT218 for Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy

- - - A total of 212 patients enrolled in the REST-ON study exceeds the trial’s enrollment target of 205 - - - Topline data from the REST-ON study expected in Q2 2020 DUBLIN, Ireland , Dec. 17, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing

Avadel Pharmaceuticals Receives U.S. FDA Approval for Nouress™ (AV001), a Cysteine Hydrochloride Injection for Treating Neonate Patients Requiring Total Parental Nutrition (TPN)

USPTO issues Orange Book-listed patent for Nouress DUBLIN, Ireland , Dec. 16, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating narcolepsy, announced today that the

Avadel Pharmaceuticals Appoints Dr. Mark McCamish to its Board of Directors

DUBLIN, Ireland , Dec. 10, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating narcolepsy, announced today the appointment of Mark McCamish , MD, Ph.D.

Avadel Pharmaceuticals Announces Key Appointments to Leadership Team To Support Continued Transformation and the Advancement of FT218

- - - Thomas S. McHugh appointed as Chief Financial Officer - - - Dr. Jason Vaughn appointed Senior Vice President of Technical Operations DUBLIN, Ireland , Dec. 02, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational,

Avadel Pharmaceuticals Achieves Enrollment Target in REST-ON Phase 3 Pivotal Trial of FT218 for Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy

205 patients enrolled; additional patients currently in screening will be allowed to enroll if eligible Topline data from the REST-ON study expected in Q2 2020 DUBLIN, Ireland , Nov. 25, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an

Avadel Pharmaceuticals to Present at Two Upcoming Investor Conferences

DUBLIN, Ireland , Nov. 21, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating narcolepsy, announced today that its Chief Executive Officer, Greg Divis , will present

Avadel Pharmaceuticals Reports Third Quarter 2019 Financial Results and Raises Revenue Guidance for FY2019

Enrollment currently at 200 patients for the pivotal REST-ON Phase 3 study (97.5% complete); the Company currently expects to complete patient enrollment by end of 2019, with data readout expected in Q2 2020 Revenue of $48.2 million for first nine months of 2019; increasing revenue guidance to be

Avadel Pharmaceuticals to Report Third Quarter 2019 Financial Results on November 12th

DUBLIN, Ireland , Oct. 29, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating narcolepsy, today announced that it will host a conference call and live webcast at 8:30

Avadel Announces Resignation of Kevin Kotler from Board of Directors

DUBLIN, Ireland , Oct. 04, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, a once-nightly formulation of sodium oxybate, for narcolepsy, today announced that Kevin Kotler , the Managing Member of Broadfin Capital, LLC , has resigned from

Avadel Pharmaceuticals Announces Pharmacokinetic (PK) Data for Once-Nightly FT218 that will be Included in an Oral Presentation at the World Sleep 2019 Congress on September 25th

DUBLIN, Ireland , Sept. 24, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate, for narcolepsy, today announced pharmacokinetic (PK) data for FT218 from four Phase 1 studies

Avadel Pharmaceuticals Announces FDA Agreement to Reduce the Sample Size for the Ongoing Pivotal Phase 3 Study for Once-Nightly FT218; Full Enrollment Now Expected by End of 2019

FDA agrees with Company’s proposed changes to the statistical analysis plan for the REST-ON Phase 3 study for once-nightly sodium oxybate, FT218 Reduces estimated time to completion by up to 12 months; now expected to complete patient enrollment by end of 2019, with pivotal data readout now

Avadel Pharmaceuticals Announces an Oral Presentation on Investigational Once-Nightly Sodium Oxybate (FT218) at the World Sleep 2019 Congress on September 25th

DUBLIN, Ireland , Sept. 18, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218 for narcolepsy, today announced that Dr. Michael Thorpy , Director of the Sleep-Wake Disorders Center at the Montefiore Medical Center , will be providing an oral

Avadel Pharmaceuticals to Present at the Ladenburg Thalmann 2019 Healthcare Conference on September 24th

DUBLIN, Ireland , Sept. 17, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, a once-nightly formulation of sodium oxybate, for narcolepsy, today announced that its Chief Executive Officer, Greg Divis , will present at the Ladenburg Thalmann

Avadel Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Company Update

Better-than-expected Hospital Product revenue improves liquidity position Restructuring and other cost reduction actions on track to realize $80 to $90 million in annualized cost savings REST-ON 69% enrolled; 81 patients remain to be enrolled DUBLIN, Ireland , Aug.

Avadel Pharmaceuticals Receives New PDUFA Date for AV001 of December 15, 2019

PDUFA Action Extended 3 Months; Launch Remains on Track for 1Q 2020 DUBLIN, Ireland , Aug. 08, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218 for narcolepsy, today announced that the U.S. Food and Drug Administration ( FDA ) has extended

Avadel Pharmaceuticals Further Strengthens Clinical and Medical Team

Appoints Courtney Wells as Vice President, Clinical Operations; and David Seiden, M.D., as Senior Medical Director, Clinical Development and Medical Affairs DUBLIN, Ireland , Aug. 01, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218 for

Avadel Pharmaceuticals to Report Second Quarter 2019 Financial Results

DUBLIN, Ireland , July 29, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218 for narcolepsy, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. EDT on Friday, August 9, 2019 , to provide a corporate

Avadel to Present New Data on Once-Nightly Sodium Oxybate at SLEEP 2019 Conference

DUBLIN, Ireland , June 04, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218 for narcolepsy, today announced it will present two posters at the 33 rd Annual Meeting of the Associated Professional Sleep Societies being held in San Antonio,

Avadel Pharmaceuticals Appoints Gregory J. Divis Chief Executive Officer

DUBLIN, Ireland , June 03, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218 for narcolepsy, today announced the appointment of Gregory J. Divis as Chief Executive Officer and member of the Board of Directors. Mr.

Avadel Pharmaceuticals Announces FDA Acceptance of New Drug Application for AV001

AV001 granted Priority Review PDUFA action date is September 15, 2019 DUBLIN, Ireland , May 22, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), today announced that the U.S. Food and Drug Administration ( FDA ) has accepted the New Drug Application (NDA) for the Company’s

Avadel Pharmaceuticals Reports First Quarter 2019 Financial Results

REST-ON 63% enrolled; 98 patients remain to be enrolled Jordon Dubow , M.D., appointed as Chief Medical Officer Noctiva™-related assets sold; all operational activities have ceased DUBLIN, Ireland , May 08, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on

Avadel Pharmaceuticals Announces Appointment of Jordan Dubow, M.D., as Chief Medical Officer

DUBLIN, Ireland , April 29, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218 for sleep disorders, today announced that it has appointed Jordan Dubow , M.D., as Chief Medical Officer. Dr. Dubow brings extensive experience leading clinical

Avadel Pharmaceuticals to Report First Quarter 2019 Financial Results

DUBLIN, Ireland , April 29, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218 for sleep disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. EDT on Wednesday, May 8, 2019 , to provide a

Avadel Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results

DUBLIN, Ireland , March 15, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218 for sleep disorders, today announced its financial results for the fourth quarter and full year of 2018. "We have recently announced a restructuring and other

Avadel Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results

DUBLIN, Ireland , March 07, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218 for sleep disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. EDT on Friday, March 15, 2019 , to provide a

Avadel Pharmaceuticals Clarifies Announcement of Corporate Restructuring

DUBLIN, Ireland , Feb. 07, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) provided clarification regarding the restructuring actions announced earlier today. As part of the restructuring plan, Avadel Specialty Pharmaceuticals, LLC , a special purpose entity and wholly-owned

Avadel Pharmaceuticals Announces Restructuring to Focus on FT218 Clinical Development Program

- Company cost structure expected to be reduced by $70 to $75 million in 2019 – - Approximately $100 million in cash and marketable securities at December 31, 2018 – DUBLIN, Ireland , Feb. 07, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), today announced a corporate

‘Sleep Normal’ campaign urges Americans to end frequent nighttime urination and stop settling for nights of bad sleep

Nearly 50 million Americans wake up to urinate more than once per night due to a treatable medical condition called nocturia WASHINGTON , Jan. 23, 2019 (GLOBE NEWSWIRE) -- A new awareness campaign called ‘Sleep Normal’ launched Monday to raise awareness of nocturia, an underdiagnosed, treatable,

Avadel Pharmaceuticals Announces Changes to Management Team and Board of Directors

- Michael S. Anderson resigns as Chief Executive Officer and member of Avadel’s Board of Directors – - Gregory J. Divis , current Avadel Chief Operating Officer, named Interim Chief Executive Officer – - Geoffrey M. Glass , current member of Avadel’s Board of Directors, named Chairman, replacing

Avadel Pharmaceuticals Appoints Kevin Kotler to the Company’s Board of Directors

DUBLIN, Ireland , Dec. 11, 2018 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on providing innovative medicines for chronic urological, central nervous system, and sleep disorders, today announced that Kevin Kotler , the founder and Portfolio Manager of Broadfin

As Waking Up Multiple Times a Night to Urinate Can Lead to Memory Deficits, Obesity, Lowered Sex Drive, Falls and Depression, a New Council Urges Awareness and Action

Advocacy and Industry Form Nocturia Council to Sound the Alarm That Waking Up Multiple Times at Night to Urinate, a Treatable Medical Condition Called Nocturia, Is Causing Distressing Health Issues WASHINGTON , Nov. 29, 2018 (GLOBE NEWSWIRE) -- Nov. 25-30 acknowledges Nocturia Awareness Week , part

Avadel Pharmaceuticals Reports Third Quarter 2018 Financial Results

DUBLIN, Ireland , Nov. 05, 2018 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on providing innovative medicines for chronic urological, central nervous system, and sleep disorders, today announced its financial results for the third quarter of 2018.

Avadel Presents Data on Quality of Life Improvement in Patients on NOCTIVA™ at American Urological Association Western Annual Meeting

Patients treated with NOCTIVA were three times more likely to report no difficulty getting enough sleep and five times more likely to report no bother due to nocturia DUBLIN, Ireland , Oct. 29, 2018 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on providing

Avadel Pharmaceuticals to Report Third Quarter 2018 Financial Results

DUBLIN, Ireland , Oct. 25, 2018 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on providing innovative medicines for chronic urological, central nervous system, and sleep disorders, today announced it will report its third quarter 2018 financial results on Monday,

Avadel Pharmaceuticals Presents Data for NOCTIVA at 2018 American Urogynecologic Society Annual Scientific Meeting

Data demonstrate significant improvement in number of nights with one or no nocturic episodes and extended first uninterrupted sleep period in patients suffering from nocturia due to nocturnal polyuria DUBLIN, Ireland , Oct. 15, 2018 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a

Avadel Pharmaceuticals Announces Journal of Urology Publication of Phase 3 Data on NOCTIVA

NOCTIVA is the first treatment approved by the FDA to treat nocturia in adults due to nocturnal polyuria DUBLIN, Ireland , Sept. 28, 2018 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on providing innovative medicines for chronic urological, central nervous

Avadel Pharmaceuticals to Present at the Ladenburg Thalmann 2018 Healthcare Conference

DUBLIN, Ireland , Sept. 25, 2018 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on providing innovative medicines for chronic urological, central nervous system, and sleep disorders, today announced that its Chief Operating Officer, Greg Divis , will present at the

The medical condition 72 percent of Americans don’t know about is stealing sleep and disrupting lives, survey shows

Over one-third of Americans wake up more than once per night to urinate due to a condition called nocturia, which can cause daytime tiredness and irritability, impair work productivity, increase risk of falls and injury, and lead to other medical problems WASHINGTON , Sept.

Avadel Pharmaceuticals to Present at the 2018 Wells Fargo Healthcare Conference

DUBLIN, Ireland , Aug. 30, 2018 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq:AVDL), a company focused on providing innovative medicines for chronic urological, central nervous system, and sleep disorders, today announced that its Chief Executive Officer, Mike Anderson , will present at

New Data on NOCTIVA™ Presented at the 2018 International Continence Society Meeting

Data demonstrate meaningful reduction in nocturic episodes, extended first uninterrupted sleep period, and improved quality of life for patients suffering from nocturia due to nocturnal polyuria DUBLIN, Ireland , Aug. 29, 2018 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company

Avadel Pharmaceuticals Reports Second Quarter 2018 Financial Results

DUBLIN, Ireland , Aug. 07, 2018 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ: AVDL), a company focused on providing innovative medicines for chronic urological, central nervous system, and sleep disorders, today announced its financial results for the second quarter of 2018.

Avadel Pharmaceuticals to Report Second Quarter 2018 Results

DUBLIN, Ireland , July 17, 2018 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq:AVDL), today announced it will report its second quarter 2018 financial results on Tuesday, August 7, 2018 , before the market open. A conference call to discuss these results has been scheduled for Tuesday,

Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

DUBIN, Ireland , May 31, 2018 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq:AVDL), “Avadel” or the “Company,” today announced that management will present at two upcoming investor conferences: The Jefferies 2018 Healthcare Conference on Friday, June 8, 2018 at 11:00 a.m.

Avadel to Present Late-Breaker Data and Product Theater Forum at the 2018 American Urological Association Annual Meeting

Data demonstrates extended first uninterrupted sleep period in elderly patients Key opinion leaders to present “NOCTIVA™: Addressing a Nighttime Condition with Daytime Consequences” DUBLIN, Ireland , May 18, 2018 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq:AVDL), “Avadel” or the

Avadel Pharmaceuticals Reports First Quarter 2018 Results

NOCTIVA™ launch underway across the U.S. FT 218 granted Orphan Drug Designation Generated revenue of $33.3 million DUBLIN, Ireland , May 02, 2018 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL) today announced its financial results for the first quarter of 2018.

Avadel Launches NOCTIVA™, the First and Only FDA-Approved Treatment for Nocturia Due to Nocturnal Polyuria

Innovative product now available in the United States for condition that interrupts sleep for over 40 million Americans DUBLIN, Ireland , May 01, 2018 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq:AVDL) today announced the launch of NOCTIVA™ (desmopressin acetate), an emulsified microdose

Avadel Pharmaceuticals to Present at the Deutsche Bank 43rd Annual Health Care Conference

DUBLIN, Ireland , April 30, 2018 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq:AVDL), “Avadel” or “the Company,” today announced that Greg Divis , Chief Operating Officer, and Mike Kanan , Chief Financial Officer, will present at the Deutsche Bank 43rd Annual Health Care Conference on

Avadel Pharmaceuticals to Report First Quarter 2018 Results

DUBLIN, Ireland , April 24, 2018 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq:AVDL), today announced it will report its first quarter 2018 financial results on Wednesday, May 2, 2018 , before the market open. A conference call to discuss these results has been scheduled for Wednesday, May

Avadel Pharmaceuticals Announces Acceptance of Late-Breaker Presentation for NOCTIVA™ at the 2018 American Urological Association

DUBLIN, Ireland , April 03, 2018 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq:AVDL), “Avadel” or the “Company,” today announced that new data from NOCTIVA’s pivotal Phase III clinical trials will be presented at the American Urological Association (AUA) 2018 annual meeting in San

Avadel Pharmaceuticals Announces Promotion of Gregory J. Divis to Chief Operating Officer

DUBLIN, Ireland , March 22, 2018 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), “Avadel” or the “Company,” today announced the promotion of Gregory J. Divis to Executive Vice President and Chief Operating Officer, a newly created role at the Company. Mr.

Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

DUBLIN, Ireland , March 09, 2018 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq AVDL), “Avadel” or “the Company,” today announced that management will present at two upcoming investor conferences: The 30 th Annual ROTH Conference on Tuesday, March 13, 2018 at 1:30 p.m.

Avadel Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Results

Fourth quarter and full year revenues of $34.2 million and $172.7 million, respectively DUBLIN, Ireland , March 08, 2018 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq:AVDL), "Avadel" or "the Company," today announced its financial results for the fourth quarter and full year 2017.

Avadel Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Results

DUBLIN, Ireland , Feb. 26, 2018 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), today announced it will report its fourth quarter and full year 2017 financial results on Thursday, March 8, 2018 , before the market open. A conference call to discuss these results has been scheduled for

Avadel Pharmaceuticals Announces Pricing of $125.0 Million 4.50% Exchangeable Senior Notes due 2023

DUBLIN, Ireland , Feb. 14, 2018 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq:AVDL) (“Avadel” or “the Company”) today announced that its wholly-owned subsidiary, Avadel Finance Cayman Limited (the “Issuer”), priced its previously announced offering of $125,000,000 aggregate principal

Avadel Pharmaceuticals Announces Proposed Exchangeable Senior Notes Offering

DUBLIN, Ireland , Feb. 13, 2018 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq:AVDL) (“Avadel” or “the Company”) today announced that its wholly-owned subsidiary, Avadel Finance Cayman Limited (the “Issuer”), intends to offer, subject to market and other conditions, $125,000,000 principal

Avadel Pharmaceuticals Announces Divestiture of Pediatric Business

Cerecor to acquire Avadel’s pediatric assets Enters into license agreement to develop four LiquiTime ™ or Micropump ® products DUBLIN, Ireland , Feb. 12, 2018 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL) (“Avadel” or “the Company”) today announced that it has entered into an asset

Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for FT 218 for the Treatment of Narcolepsy

DUBLIN, Ireland , Jan. 10, 2018 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), “Avadel” or “the Company,” today announced that FT 218 has been granted Orphan Drug Designation from the U.S. Food and Drug Administration ( FDA ) for the treatment of narcolepsy.

Avadel Pharmaceuticals Issues 2018 Corporate Outlook

Commercial launch for Noctiva™ on target for second quarter 2018 NDA filing for FT218 expected by year-end 2018 Total revenues expected to range from $110 - 130 million DUBLIN, Ireland , Dec. 29, 2017 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), “Avadel” or “the Company,” today

Avadel Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare Conference

DUBLIN, Ireland , Nov. 27, 2017 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), today announced that Mike Kanan , Chief Financial Officer, and Lauren Stival , Senior Director, Investor Relations, will participate in a fireside chat at the 29th Annual Piper Jaffray Healthcare

Avadel Pharmaceuticals Reports Third Quarter 2017 Results

Total Revenues for the Third Quarter Were $39.7 Million Full Year Revenue Guidance of $165-$175 Million Unchanged Acquired License for Noctiva ™ DUBLIN, Ireland , Nov. 08, 2017 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL) today announced its financial results for the third quarter

Avadel Pharmaceuticals to Host Analyst and Investor Meeting

DUBLIN, Ireland , Nov. 06, 2017 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), today announced it will host an analyst and investor meeting to focus on its new product, Noctiva™, on Monday, November 13, 2017 in New York City . The presentation will take place from approximately 8:00

Avadel Pharmaceuticals to Report Third Quarter 2017 Results

DUBLIN, Ireland , Oct. 20, 2017 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), today announced it will report its third quarter 2017 financial results on Wednesday, November 8, 2017 , before the market open. A conference call to discuss these results has been scheduled for Wednesday,

Avadel Pharmaceuticals Announces Data Presentation for Noctiva™ at The American Urogynecologic Society’s Annual Scientific Meeting

DUBLIN, Ireland , Oct. 05, 2017 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), announced that data for the clinical evaluation of Noctiva (previously “SER120”) for the treatment of patients with nocturia due to nocturnal polyuria with concomitant overactive bladder (OAB) will be

Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

DUBLIN, Ireland , Sept. 13, 2017 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), today announced that management will present at two upcoming investor conferences: The Ladenburg Thalmann 2017 Healthcare Conference on Tuesday, September 26, 2017 at 12:00 p.m.

Avadel Pharmaceuticals Enters into Exclusive License Agreement for Noctiva™

Noctiva is the only FDA-approved product indicated for the treatment of nocturia DUBLIN, Ireland , Sept. 05, 2017 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL) (“Avadel”), today announced that it has entered into a license agreement with Serenity Pharmaceuticals, LLC (“Serenity”).

Avadel Pharmaceuticals to Present at the 2017 Wells Fargo Healthcare Conference

DUBLIN, Ireland , Aug. 29, 2017 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), today announced that management will present at the 2017 Wells Fargo Healthcare Conference on Thursday, September 7, 2017 at 10:35 am EDT . A live audio webcast of the presentation can be accessed at the

Avadel Pharmaceuticals Enters into Exclusive Negotiations with Serenity Pharmaceuticals for Noctiva™

DUBLIN, Ireland , Aug. 17, 2017 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL) (“Avadel”), today announced that it has entered into an agreement for the right to exclusively negotiate with Serenity Pharmaceuticals, LLC (“Serenity”), for the sole rights to commercialize and further

Avadel Pharmaceuticals Reports Second Quarter 2017 Results

Total Revenues Increased 19% on a Year-Over-Year Basis to $46.3 Million Strong Year-to-Date Operating Cash Flow of $33.5 Million DUBLIN, Ireland , Aug. 08, 2017 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL) today announced its financial results for the second quarter of 2017.

Avadel Pharmaceuticals to Report Second Quarter 2017 Results

DUBLIN, Ireland , July 20, 2017 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), today announced it will report its second quarter 2017 financial results on Tuesday, August 8, 2017 , before the market open. A conference call to discuss these results has been scheduled for Tuesday,

Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

DUBLIN, Ireland , May 30, 2017 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), today announced that management will present at two upcoming investor conferences: Jefferies 2017 Healthcare Conference on Thursday, June 8, 2017 at 3:30 p.m. Eastern Time in New York City The 2017 JMP

Avadel Pharmaceuticals Supports the Narcolepsy Network's 5th Annual DREAM BIG Walk

DUBLIN, Ireland , May 17, 2017 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), today announced that on Sunday, May 14, 2017 the Company supported the Narcolepsy Network’s 5 th Annual DREAM BIG Walk in New York City and Seattle . The annual walks raise funding for the Narcolepsy

Avadel Pharmaceuticals Reports First Quarter 2017 Results

Total Revenues of $52.5 million, Highest Quarterly Revenue in Company History DUBLIN, Ireland , May 09, 2017 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL) today announced its financial results for the first quarter of 2017. Highlights Include: Total revenues for the first quarter

Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

DUBLIN, Ireland , April 24, 2017 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), today announced that management will present at two upcoming investor conferences: Deutsche Bank 42 nd Annual Healthcare Conference on Wednesday, May 3, 2017 at 1:30 p.m.

Avadel Pharmaceuticals to Report First Quarter 2017 Results

DUBLIN, Ireland , April 17, 2017 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), today announced it will report its first quarter 2017 financial results on Tuesday, May 9, 2017 , before the market open. A conference call to discuss these results has been scheduled for Tuesday, May 9,

Avadel Pharmaceuticals Announces Planned Reduction of French Workforce

DUBLIN, Ireland , March 30, 2017 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), today announced a plan to reduce its headcount in France by approximately 50 people. This reduction is an effort to align the Company’s cost structure with its ongoing and future planned projects.

Avadel Pharmaceuticals Announces $25 Million Share Repurchase Program

DUBLIN, Ireland , March 07, 2017 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), today announced that the Company’s board of directors has authorized the repurchase of up to $25 million of the Company’s ordinary shares, represented by American Depository Shares (ADS) which are listed

Avadel Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Results

Strong Fourth Quarter Revenues of $43.1 Million Drive Full Year Revenues of $150.2 Million Reaffirms 2017 Revenue Guidance of $170 - $200 Million and Adjusted EPS of $0.20 - $0.35 DUBLIN, Ireland , March 07, 2017 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL) today announced its

Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

DUBLIN, Ireland , March 02, 2017 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), today announced that management will present at two upcoming investor conferences: The 29 th Annual ROTH Conference on Monday, March 13, 2017 at 4:00 p.m. Pacific Time in Dana Point, California

Avadel Pharmaceuticals to Report Fourth Quarter and Full Year 2016 Results

DUBLIN, Ireland , Feb. 14, 2017 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), today announced it will report its fourth quarter and full year 2016 financial results on Tuesday, March 7, 2017 , before the market open. A conference call to discuss these results has been scheduled for

Avadel Pharmaceuticals to Present at Two Upcoming Investor Conferences

DUBLIN, Ireland , Feb. 06, 2017 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), today announced that management will present at two upcoming investor conferences: LEERINK Partners 6 th Annual Global Healthcare Conference on Wednesday, February 15, 2017 at 9:00 a.m.

Avadel Pharmaceuticals Provides 2017 Guidance and Business Update

Full Year 2017 Revenue Guidance of $170 - $200 million Adjusted Diluted EPS of $0.20 - $0.35 DUBLIN, Ireland , Jan. 05, 2017 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), today announced 2017 financial guidance and outlined a number of key business objectives for the year, including

Avadel Pharmaceuticals Appoints Gregory J. Divis Chief Commercial Officer

DUBLIN, Ireland , Jan. 03, 2017 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL) today announced the addition of Gregory J. Divis as Executive Vice President and Chief Commercial Officer, a newly created role at the Company. Mr. Divis brings more than 25 years of experience in the

Flamel Technologies Completes Cross-Border Merger and Becomes Avadel Pharmaceuticals plc

DUBLIN, Ireland , Jan. 03, 2017 (GLOBE NEWSWIRE) -- Flamel Technologies SA , completed its previously announced cross-border merger with and into its wholly-owned Irish subsidiary, Avadel Pharmaceuticals plc (NASDAQ:AVDL) (Avadel), effective January 1, 2017 , with Avadel surviving the merger as the

Flamel Technologies Doses First Patient in REST-ON Phase III Trial of FT218 for Excessive Daytime Sleepiness & Cataplexy

Flamel Technologies to Present at Jefferies 2016 London Healthcare Conference

Flamel Technologies Reports Third Quarter 2016 Results

Flamel Technologies to Report Third Quarter 2016 Results

Flamel Technologies Reaches Agreement with FDA on Protocol for Phase III Pivotal Trial of FT218

Flamel Technologies to Present at Ladenburg Thalmann 2016 Healthcare Conference

Flamel Technologies to Host Investor & Analyst Meeting

Flamel Technologies Hires Vice President of Sales

Flamel Technologies Launches Akovaz™

Flamel Technologies Announces Shareholder Approval of Cross-Border Merger

Flamel Technologies Reports Second Quarter 2016 Results

Flamel Technologies to Report Second Quarter 2016 Results

Flamel Technologies to Present at Two Upcoming Investor Conferences

Flamel Technologies Reports First Quarter 2016 Results

Flamel Technologies to Report First Quarter 2016 Results

Flamel Technologies Receives FDA Approval of Akovaz™

Flamel Technologies to Present at Upcoming Investor Conferences

Flamel Technologies Files Special Protocol Assessment for Once Nightly Sodium Oxybate

Flamel Technologies Reports Fourth Quarter and Full Year 2015 Results

Flamel Technologies to Present at the 28th Annual ROTH Conference

Flamel Technologies to Report Fourth Quarter and Full Year 2015 Results

Flamel Technologies to Present at RBC Capital Markets' 2016 Global Healthcare Conference

Flamel Technologies Acquires FSC Pediatrics

Flamel Technologies Provides Update on Corporate Progress

Flamel Technologies Announces Positive Interim Results of a First-in-Man Clinical Trial with Medusa™ Exenatide

Flamel Technologies Appoints Michael Kanan Chief Financial Officer

Flamel Technologies Reports Third Quarter 2015 Results

Flamel Technologies to Report Third Quarter 2015 Results

Flamel Ireland Limited Licenses LiquiTime® Technology to Perrigo for U.S. Over-the-Counter Market

Flamel Technologies to Present at Ladenburg Thalmann 2015 Healthcare Conference

Flamel Technologies Announces FDA Acceptance of Third NDA Filing

Flamel Technologies Announces Second Quarter Results of Fiscal Year 2015

Flamel Technologies Announces Results of 2015 Annual Meeting; Domestic U.S. Public Company Reporting Status to Begin in 2016

Flamel Technologies to Report Second Quarter of Fiscal Year 2015 Results

Flamel Technologies Announces Positive Results From First Clinical Trials With Trigger Lock™ Hydromorphone Abuse-Deterrent Product

Flamel Technologies Appoints SVP of Quality and Regulatory Affairs and VP of Business and Corporate Development

Flamel Technologies to Present at JMP Securities Life Sciences Conference

Flamel Technologies to Present at Jefferies 2015 Healthcare Conference

Flamel Technologies Announces First Quarter Results of Fiscal Year 2015

Flamel Technologies to Report First Quarter of Fiscal Year 2015 Results

Flamel Technologies Announces Departure of Senior Vice President of Business and Corporate Development

Flamel Technologies Announces Positive Results of a First-in-Man Clinical Trial with LiquiTime® Guaifenesin

Flamel Technologies Announces Fourth Quarter and Full Year Results of Fiscal Year 2014

Flamel Technologies to Report Fourth Quarter of Fiscal Year 2014 Results

Flamel Technologies to Present at Two Upcoming Investor Conferences

Flamel Technologies Announces Price Change for Bloxiverz

Flamel Technologies Announces Positive Results of a Second Clinical Trial with Micropump® Sodium Oxybate

Flamel Technologies Transfers Intangible Property to Irish-Based Subsidiary in Global Reorganization

Flamel Technologies to be Included in NASDAQ Biotech Index

Flamel Technologies Closes Sale of Development and Manufacturing Facility in Pessac, France to Recipharm AB

Flamel Technologies Sells Development and Manufacturing Facility in Pessac, France to Recipharm AB

Flamel Technologies Announces Third Quarter Results of Fiscal Year 2014

Flamel Technologies to Report Third Quarter of Fiscal Year 2014 Results

Flamel Technologies Announces Positive Results of First-in-Man Clinical Trial with LiquiTime® Ibuprofen

Flamel Technologies Announces Plan to Appoint New VP of R&D

Flamel Notified of FDA Communication to Unapproved Manufacturers of Neostigmine Methylsulfate

Flamel Technologies Announces Second Quarter of Fiscal Year 2014 Results

Flamel Technologies to Report Second Quarter of Fiscal Year 2014 Results

Flamel Technologies Announces Results of 2014 Annual Meeting

Flamel Technologies Announces Positive Preclinical Results For Its Once-A-Week Formulation of Exenatide

Flamel Technologies Receives Class 1 Response Designation for Second NDA

Flamel Technologies Announces Intent to Resubmit Second NDA

Flamel Technologies Announces First Quarter of Fiscal Year 2014 Results

Flamel Technologies to Report First Quarter of Fiscal Year 2014 Results

1 Flamel Technologies Announces Receipt of Complete Response Letter From FDA Citing Issues at the Facility of the Supplier of the Active Ingredient

Flamel Technologies Announces Positive Results of a First-in-Man Clinical Trial with Micropump® Sodium Oxybate

Flamel Technologies Announces Fourth Quarter and Full Year 2013 Results

Flamel Technologies to Report Fourth Quarter and Fiscal Year 2013 Results and Conference Call

Flamel Technologies, S.A. Announces Pricing of Public Offering of American Depositary Shares

Flamel Technologies, S.A. Announces Proposed Underwritten Public Offering of American Depositary Shares

Flamel Technologies Announces $15 Million Line of Credit

Flamel Technologies Announces Third Quarter 2013 Results

Flamel Technologies Announces Projected Release Date of Third Quarter 2013 Results and Conference Call

Flamel Technologies Announces Acceptance of FDA Review for Second NDA

Flamel Technologies Announces Second Quarter 2013 Results

Flamel Technologies Announces Projected Release Date of Second Quarter 2013 Results and Conference Call

Flamel Technologies Announces Resubmission of Second NDA

Flamel Technologies Announces Results of 2013 Annual Meeting

Flamel Technologies Announces Product Partnership Agreement

Flamel Technologies Obtains Rights to Two Molecules of Trigger Lock Product Line

Flamel Technologies Announces First Quarter 2013 Results

Flamel Technologies Announces Projected Release Date of First Quarter 2013 Results and Conference Call

Judge Dismisses 2007 Class Action Case Against Flamel Technologies

Flamel Technologies Announces $15 Million Debt Financing to Advance R&D Efforts